1246303-14-9

1246303-14-9 structure

Name: VU0359595
Chemical Name: (1R,2R)-N-{(2S)-1-[4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-2-propanyl}-2-phenylcyclopropanecarboxamide
CAS Number: 1246303-14-9
Molecular Formula: C₂₅H₂₉BrN₄O₂
Molecular Weight: 497.427
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phospholipase
Create Date: 2018-04-17 16:02:55
Modify Date: 2024-04-04 10:33:00
VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases[1][2][3][4].

Name	(1R,2R)-N-{(2S)-1-[4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-2-propanyl}-2-phenylcyclopropanecarboxamide
Synonyms	Cyclopropanecarboxamide, N-[(1S)-2-[4-(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-phenyl-, (1R,2R)- (1R,2R)-N-{(2S)-1-[4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-2-propanyl}-2-phenylcyclopropanecarboxamide

Description	VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases[1][2][3][4].
Related Catalog	Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	PLD1:3.7 nM (IC50) PLD2:6.4 μM (IC50)
In Vitro	VU0359595 (5, 50, 500, 5000 nM) inhibits basal and FCS/IGF-1 stimulated proliferation of astroglial cells[2] . VU0359595 (5, 50, 500 nM; 30 min) does not affect basal PLD activity in astrocytes but reduces mitogen-stimulated PLD activity in a concentration-dependent manner[2]. VU0359595 (0.15 μM; 1 h before high glucose treatment and 4 h during high glucose treatment) partially reduces the increase [3H]-phosphatidylethanol (PEth) generation induced by high glucose (33 mM) in retinal pigment epithelium (RPE) cells[3]. VU0359595 (5 μM; 1 h prior to LPS treatment) modulates the autophagic process of LPS-induced (10 μg/ml; 24 h) RPE cells[4].
References	[1]. Lewis JA, et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg Med Chem Lett. 2009;19(7):1916-1920. [2]. Burkhardt U, et al. Phospholipase D is a target for inhibition of astroglial proliferation by ethanol. Neuropharmacology. 2014;79:1-9. [3]. Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019;184:243-257. [4]. Bermúdez V, et al. Lipopolysaccharide-Induced Autophagy Mediates Retinal Pigment Epithelium Cells Survival. Modulation by the Phospholipase D Pathway. Front Cell Neurosci. 2019;13:154. Published 2019 Apr 24.

Density	1.4±0.1 g/cm3
Molecular Formula	C₂₅H₂₉BrN₄O₂
Molecular Weight	497.427
Exact Mass	496.147369
LogP	4.71
Index of Refraction	1.631

RIDADR	NONH for all modes of transport

1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
2138519-43-2	1018584-77-4
1375289-11-4	849349-65-1